Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
333.7 USD | +0.61% | +1.60% | +23.43% |
04:29pm | Wells Fargo Raises Price Target on HCA Healthcare to $315 From $303, Maintains Equalweight Rating | MT |
02:32pm | Ondine Biomedical appoints new interim chief financial officer | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.43% | 87.73B | C+ | ||
+1.17% | 99.96B | B- | ||
+10.42% | 29.33B | C+ | ||
-4.01% | 18.21B | B | ||
-3.24% | 14.51B | A- | ||
+20.26% | 12.22B | B- | ||
+31.62% | 12B | B- | ||
+0.17% | 11.94B | A- | ||
-13.00% | 11.63B | B- | ||
-32.28% | 11.56B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock HCA Healthcare, Inc. - Nyse
- Ratings HCA Healthcare, Inc.